Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study

NCT07752550 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07752550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07752550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 30, 2026
Completion date
July 30, 2029
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer (tnbc)